The FUSE Cage is indicated for intervertebral body spinal fusion procedures in skeletally mature patients with degenerative disc disease (DDD) at one or two contiguous levels from L2-S1. DDD is defined as discogenic back pain with degeneration of the disc confirmed by patient history and radiographic studies. These DDD patients may also have up to Grade I spondylolisthesis or retrolisthesis at the involved level(s). FUSE implants are to be used with autogenous bone graft and implanted via an open posterior approach. The FUSE Cage is to be used with supplemental fixation. Patients should have at least six (6) months of non-operative treatment prior to treatment with an intervertebral cage.

Device Description

The FUSE is rectangular in shape and it has a honeycomb structure thru the implant in the superior/inferior direction. There is an oval opening in the M/L direction. There is a roughened surface on the superior and inferior surfaces. There are neutral, 4° and 8° lordosis configurations. The posterior end has a threaded hole for attaching insertion instruments, while the other end is solid and tapered.

AI/ML Overview

The provided text describes a medical device, the AMT FUSE Cage, and its 510(k) summary for FDA clearance. However, it does not contain any information about acceptance criteria, specific device performance metrics, or any study design that would "prove" the device meets such criteria in the context of AI/machine learning or diagnostic accuracy.

The information provided is typical for a 510(k) submission for a non-active implantable medical device, focusing on substantial equivalence to a predicate device based on design, materials, function, and mechanical testing.

Therefore, I cannot populate the requested table or answer most of the questions, as the source document does not contain this type of information.

Here's what I can extract and explain:

Summary of Information from the Provided Text:

The document is a 510(k) premarket notification for the AMT FUSE Cage, a device intended for intervertebral body spinal fusion. The FDA determined the device is substantially equivalent to legally marketed predicate devices.

Missing Information:

The provided text does not contain any information related to:

Acceptance criteria for performance metrics (e.g., sensitivity, specificity, accuracy).
Reported device performance (in terms of diagnostic accuracy or AI performance).
Sample size used for a test set or training set.
Data provenance (country of origin, retrospective/prospective).
Number of experts or their qualifications for ground truth.
Adjudication methods.
Multi-reader multi-case (MRMC) comparative effectiveness studies.
Standalone algorithm performance studies.
Type of ground truth used (pathology, outcomes data, expert consensus).
How ground truth for a training set was established.

This is because the device described is a physical implant (a spinal cage), not an AI/ML-driven diagnostic or image analysis tool. The "study" mentioned refers to non-clinical mechanical tests, not clinical performance or diagnostic accuracy.

What is included (and why the requested AI/ML-related questions are not applicable):

The document states:

Device Name: FUSE Cages
Intended Use: Intervertebral body spinal fusion procedures in skeletally mature patients with degenerative disc disease (DDD) at one or two contiguous levels from L2-S1. To be used with autogenous bone graft and supplemental fixation via an open posterior approach, after 6 months of non-operative treatment.
Material: Commercially pure titanium.
Function: Posterior stabilization of the lumbar spinal column with the technique of Posterior Lumbar Interbody Fusion (PLIF).
Comparison to Predicate: "The AMT FUSE Cage has the same indications and material, and similar designs as previously cleared devices." (Predicate device: WAVE (K080401)).
Nonclinical Tests: "Tests performed according to ASTM F2077/F2267 indicate that the AMT FUSE Cage meets required mechanical strengths." These are mechanical strength tests relevant to the physical stability and integrity of the implant, not performance related to AI or diagnostic accuracy.

Summary

{0}------------------------------------------------

K1600945

510(k) Summary for the AMT FUSE Cage

FEB - 9 2011

In accordance with 21 CFR 807.92 of the Federal Code of Regulations the following 510(k) summary is submitted for the AMT FUSE /Cage.

Date Prepared: March 31, 2010

Submitter: ﻨﻴﺔ Contact Person: Advanced Medical Technologies AG J.D. Webb Kasteler Strasse 11 The OrthoMedix Group, Inc. 66620 Nonnweiler-Braunhausen 1001 Oakwood Blvd Round Rock, TX 78681 Germany Telephone: 512-388-0199
1. Trade name: FUSE Cages Common Name: intervertebral body fusion device Classification Name: intervertebral body fusion device - lumbar 21 CFR section 888.3080 MAX Class II
1. Predicate or legally marketed devices which are substantially equivalent: WAVE (K080401)

4. Description of the device:

Materials:

Commercially pure titanium

Function:

The FUSE Cage was developed as an implant for the posterior stabilization of the lumbar spinal column with the technique of Posterior Lumbar Interbody Fusion (PLIF).

Intended Use:

The FUSE Cage is indicated for intervertebral body spinal fusion procedures in skeletally mature patients with degenerative disc disease (DDD) at one or two contiguous levels from L2-51. DDD is defined as discogenic back pain with degeneration of the disc confirmed by patient history and radiographic studies. These DDD patients may also have up to Grade I spondylolisthesis at the involved level(s). FUSE implants are to be used with autogenous bone graft and implanted via an open posterior approach. The FUSE Cage is to be used with supplemental fixation. Patients should have at least six (6) months of non-operative treatment prior to treatment with an intervertebral cage.

Comparison of the technological characteristics of the device to predicate and legally marketed devices: ഗ്

The AMT FUSE Cage has the same indications and material, and similar designs as previously cleared devices.

6. Summary of Nonclinical Tests

Tests performed according to ASTM F2077/F2267 indicate that the AMT FUSE Cage meets required mechanical strengths.

$$\mu_* \star \star$$

{1}------------------------------------------------

Image /page/1/Picture/1 description: The image shows the logo for the Department of Health & Human Services USA. The logo is circular, with the words "DEPARTMENT OF HEALTH & HUMAN SERVICES USA" arranged around the perimeter of the circle. In the center of the circle is an abstract symbol that resembles an eagle or other bird in flight. The symbol is composed of three curved lines that converge at the bottom.

Public Health Service

Food and Drug Administration 10903 New Hampshire Avenue Document Control Room -WO66-G609 Silver Spring. MD 20993-0002

Advanced Medical Technologies AG % The OrthoMedix Group, Inc. Mr. J.D. Webb 1001 Oakwood Boulevard Round Rock, Texas 78681

FEB - 9 2011

Re: K100945

Trade/Device Name: FUSE Cages Regulation Number: 21 CFR 888.3080 Regulation Name: Intervertebral body fusion device Regulatory Class: Class II Product Code: MAX Dated: January 20, 2011 Received: January 26, 2011

Dear Mr. Webb:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration. listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you; however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act

{2}------------------------------------------------

Page 2 - Mr. J.D. Webb

or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820): and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fdagov/AboutFDA/CentersOffices/CDRH0ffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding of adverse events under the MDR regulation (21 CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm.

Sincerely yours,

M. B. Roster
for

Mark N. Melkerson Director Division of Surgical, Orthopedic And Restorative Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{3}------------------------------------------------

Indications for Use

510(k) Number (if known):

Device Name: FUSE Cage

Indications for Use:

Prescription Use X (Part 21 CFR 801 Subpart D)

AND/OR

Over-The-Counter Use _ (21 CFR 807 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE OF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Division Sign Off

(Division Sign-Off) Division of Surgical, Orthopedic, and Restorative Devices

510(k) Number K100945

Regulation Number and Section

§ 888.3080 Intervertebral body fusion device.

(a)
Identification. An intervertebral body fusion device is an implanted single or multiple component spinal device made from a variety of materials, including titanium and polymers. The device is inserted into the intervertebral body space of the cervical or lumbosacral spine, and is intended for intervertebral body fusion.(b)
Classification. (1) Class II (special controls) for intervertebral body fusion devices that contain bone grafting material. The special control is the FDA guidance document entitled “Class II Special Controls Guidance Document: Intervertebral Body Fusion Device.” See § 888.1(e) for the availability of this guidance document.(2) Class III (premarket approval) for intervertebral body fusion devices that include any therapeutic biologic (e.g., bone morphogenic protein). Intervertebral body fusion devices that contain any therapeutic biologic require premarket approval.
(c)
Date premarket approval application (PMA) or notice of product development protocol (PDP) is required. Devices described in paragraph (b)(2) of this section shall have an approved PMA or a declared completed PDP in effect before being placed in commercial distribution.